Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 308-313

  Schüle, Cornelius ^a   Baghai, Thomas C ^a   Di Michele, Flavia ^b   Eser, Daniela ^a   Pasini, Augusto ^b   Romeo, Elena ^b   Rupprecht, Rainer ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antidepressants; Major depressive disorder; Psychopharmacology; Unipolar major depression

Indexed keywords

3ALPHA,5ALPHA TETRAHYDRODEOXYCORTICOSTERONE; HYPERICUM PERFORATUM EXTRACT; MIRTAZAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TETRAHYDRODEOXYCORTICOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DESOXYCORTICOSTERONE; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIANSERIN; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950842506     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970701639429     Document Type: Article

References (29)

1. Asnis GM, Lemus CZ, Halbreich U. 1986. The desipramine cortisol test-a selective noradrenergic challenge (relationship to other cortisol tests in depressives and normals). Psychopharmacol Bull 22:571-578.
2. De Boer T. 1996. The pharmacologic profile of mirtazapine. J Clin Psychiatry 57(Suppl 4):19-25.
3. Golden RN, Ekstrom D, Brown TM, et al. 1992. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 149:1168-1175.
4. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
5. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
6. Laakmann G. 1988. Psychopharmaco-endocrinology and depression research]. Monogr Gesamtgeb Psychiatr Psychiatry Ser 46:1-220.
7. Laakmann G, Hennig J, Baghai T, Schudie; le C. 2003. Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology 47:31-36. (Pubitemid 36469784)
8. Lambert JJ, Belelli D, Hill-Venning C, Peters JA. 1995. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 16:295-303.
9. Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. 1999. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev 51:63-81.
10. Patchev VK, Shoaib M, Holsboer F, Almeida OF. 1994. The neurosteroid tetrahydroprogesterone counteracts corticotropinreleasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62:265-271.
11. Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almeida OF. 1997. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest 99:962-966.
12. Paul SM, Purdy RH. 1992. Neuroactive steroids. FASEB J 6:2311-2322.
13. Penning TM, Burczynski ME, Jez JM, et al. 2000. Human 3alphahydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77.
14. Pisu MG, Serra M. 2004. Neurosteroids and neuroactive drugs in mental disorders. Life Sci 74:3181-3197.
15. Purdy RH, Morrow AL, Moore PH Jr, Paul SM. 1991. Stressinduced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 8:4553-4557.
16. Reddy DS. 2003. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol Sci 24:103-106.
17. Rupprecht R. 2003. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28:139-168.
18. Rupprecht R, Reul JM, Trapp T, et al. 1993. Progesterone receptor-mediated effects of neuroactive steroids. Neuron 11:523-530.
19. Schudie; le C. 2007. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 19:213-226.
20. Schudie; le C, Baghai T, Bidlingmaier M, Strasburger C, Laakmann G. 2002a. Endocrinological effects of mirtazapine in healthy volunteers. Prog. Neuropsychopharmacol. Biol Psychiatry 26:1253-1261.
21. Schudie; le C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. 2002b. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berlin) 163:95-101.
22. Schudie; le C, Baghai T, Rackwitz C, Laakmann G. 2003. Influence of mirtazapine on urinary free cortisol excretion in depressed patients. Psychiatry Res 120:257-264. (Pubitemid 38366053)
23. Schudie; le C, Romeo E, Uzunov DP, et al. 2006a. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry 11:261-272. (Pubitemid 43316057)
24. Schudie; le C, Baghai TC, Eser D, et al. 2006b. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berlin) 186:601-611. (Pubitemid 43855848)
25. Schudie; le C, Baghai TC, Eser D, Schwarz M, Bondy B, Rupprecht R. 2007. Effects of mirtazapine on dehydroepiandrosteronesulfate and cortisol secretion in depressed patients. Submitted.
26. Strodie;hle A, Romeo E, Hermann B, et al. 1999. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 45:274-277. (Pubitemid 29100030)
27. Strodie;hle A, Pasini A, Romeo E, et al. 2000. Fluoxetine decreases concentrations of 3 alpha,5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res 34:183- 186. (Pubitemid 30364917)
28. Strodie;hle A, Romeo E, Di Michele F, et al. 2003. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60:161-168. (Pubitemid 36173122)
29. Wittchen HU, Wunderlich U, Zaudig M, Fydrich T. 1997. Strukturiertes Klinisches Interview fudie; r DSM-IV. Achse I: Psychische Stodie; rungen. Godie;ttingen: Hogrefe.